Stocks Reaction on News: BlackBerry Ltd (NASDAQ:BBRY), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), Celladon Corporation (NASDAQ:CLDN)
BlackBerry Ltd (NASDAQ:BBRY) released an update on its planned share buyback program to purchase for cancellation around 12M BlackBerry common shares, or approximately 2.5% of the outstanding public float. The company said the price it will pay for any shares under the share repurchase program will be the prevailing market price at the time of purchase. BlackBerry said it can purchase the common shares over the Nasdaq Stock Market or, subject to regulatory approval, on the Toronto Stock Exchange or alternative Canadian trading platforms. BlackBerry has filed a notice of intention to commence a normal course issuer bid with the TSX. BlackBerry Ltd (NASDAQ:BBRY) stock price closed at $8.63 with the total traded volume of 14.23 Million shares. Its price to sales ratio ended at 1.37. Its market capitalization is 4.55 Billion. The stock owned by the Financial Institutions was 51.80% while by insiders was 4.99%.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency (EMA) has adopted positive opinions recommending marketing authorization of Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The proposed indication for Strensiq is for long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia (HPP) to treat the bone manifestations of the disease. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has the market capitalization of 36.87 Billion. Shares of firm surged 0.50% to close at $185.90 with the total traded volume of 2.49 Million. The firm has current ratio of 4.90 for the most recent quarter.Mukesh Mali | PressKM | PressAK | Mini Militia Hack | Gossip cage
Celladon Corporation (NASDAQ:CLDN) reported that its aims to suspend further research or development of its MYDICAR (AAV1/SERCA2a) program and its other pre-clinical programs including the Stem Cell Factor or mSCF gene therapy and SERCA2b small molecule programs. Earlier in the month the Company announced the engagement of Wedbush PacGrow Healthcare as its exclusive financial advisor and a strategic plan pursuant to which the Company immediately commenced a process to seek a merger or sale. Celladon Corporation (NASDAQ:CLDN) begun last trade with a price of $1.27 and throughout the trading session climbed at a high of $1.33. The day-trade ended with -2.65% to $2.20. The stock is going forward to its 52 week low with 9.45% and lagging behind from its 52 week high price with -92.21%. CLDN last month stock price volatility remained 5.51%.
Author: Jason Dinner
